Hemophilia B Market Size, Trends, Analysis, and Outlook By Drug (Plasma Derived Coagulation Factor Concentrate, Recombinant Coagulation Factor Concentrates, Desmopressin, Others), By Treatment (On-demand, Prophylaxis), By Route of Administration (Oral, Injectable), By End-User (Hospitals, Homecare, Specialty Clinics, Others), By Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy), by Region, Country, Segment, and Companies, 2024-2030
The global Hemophilia B market size is poised to register 7.86% growth (CAGR) from 2024 to 2030, presenting significant growth prospects for companies operating in the industry. The industry study analyzes the global Hemophilia B market By Drug (Plasma Derived Coagulation Factor Concentrate, Recombinant Coagulation Factor Concentrates, Desmopressin, Others), By Treatment (On-demand, Prophylaxis), By Route of Administration (Oral, Injectable), By End-User (Hospitals, Homecare, Specialty Clinics, Others), By Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy).
The future of hemophilia B treatment is influenced by advancements in gene therapy, extended half-life factor IX products, and novel therapeutic modalities aimed at improving clotting factor replacement therapy for patients with hemophilia B. Key trends include the development of gene-based therapies utilizing adeno-associated viral vectors or mRNA technology to achieve sustained expression of functional factor IX, potentially offering a curative treatment option for this X-linked bleeding disorder. Additionally, the introduction of extended half-life factor IX products with improved pharmacokinetics and reduced dosing frequency enhances convenience and adherence to prophylactic treatment regimens, reducing the risk of spontaneous bleeds and long-term joint damage. Moreover, the exploration of non-factor replacement approaches, such as RNA interference (RNAi) and gene editing techniques, offers potential for alternative treatment modalities for patients with inhibitors or poor response to conventional factor IX replacement therapy..
Hemophilia B Market Drivers, Trends, Opportunities, and Growth Opportunities
This comprehensive study discusses the latest trends and the most pressing challenges for industry players and investors. The Hemophilia B market research analyses the global market trends, key drivers, challenges, and opportunities in the industry. In addition, the latest Future of Hemophilia B survey report provides the market size outlook across types, applications, and other segments across the world and regions. It provides data-driven insights and actionable recommendations for companies in the Hemophilia B industry.
Key market trends defining the global Hemophilia B demand in 2024 and Beyond
The industry continues to remain an attractive hub for opportunities for both domestic and global vendors. As the market evolves, factors such as emerging market dynamics, demand from end-user sectors, a growing patient base, changes in consumption patterns, and widening distribution channels continue to play a major role.
Hemophilia B Market Segmentation- Industry Share, Market Size, and Outlook to 2030
The Hemophilia B industry comprises a wide range of segments and sub-segments. The rising demand for these product types and applications is supporting companies to increase their investment levels across niche segments. Accordingly, leading companies plan to generate a large share of their future revenue growth from expansion into these niche segments. The report presents the market size outlook across segments to support Hemophilia B companies scaling up production in these sub-segments with a focus on expanding into emerging countries.
Key strategies adopted by companies within the Hemophilia B industry
Leading Hemophilia B companies are boosting investments to capitalize on untapped potential and future possibilities across niche market segments and surging demand conditions in key regions. Further, companies are leveraging advanced technologies to unlock opportunities and achieve operational excellence. The report provides key strategies opted for by the top 10 Hemophilia B companies.
Hemophilia B Market Study- Strategic Analysis Review
The Hemophilia B market research report dives deep into the qualitative factors shaping the market, empowering you to make informed decisions-
The Hemophilia B industry report provides a detailed analysis and outlook of revenue generated by companies from 2018 to 2023. Further, with actual data for 2023, the report forecasts the market size outlook from 2024 to 2030 in three case scenarios- low case, reference case, and high case scenarios.
Hemophilia B Country Analysis and Revenue Outlook to 2030
The report analyses 22 countries worldwide including the key driving forces and market size outlook from 2021 to 2030. In addition, region analysis across Asia Pacific, Europe, the Middle East, Africa, North America, and South America is included in the study. For each of the six regions, the market size outlook by segments is forecast for 2030.
North America Hemophilia B Market Size Outlook- Companies plan for focused investments in a changing environment
The US continues to remain the market leader in North America, driven by a large consumer base, the presence of well-established providers, and a strong end-user industry demand. Leading companies focus on new product launches in the changing environment. The US economy is expected to grow in 2024 (around 2.2% growth in 2024), potentially driving demand for various Hemophilia B market segments. Similarly, Strong end-user demand is encouraging Canadian Hemophilia B companies to invest in niche segments. Further, as Mexico continues to strengthen its trade relations and invest in technological advancements, the Mexico Hemophilia B market is expected to experience significant expansion, offering lucrative opportunities for both domestic and international stakeholders.
Europe Hemophilia B Market Size Outlook-Companies investing in assessing consumers, categories, competitors, and capabilities
The German industry remains the major market for companies in the European Hemophilia B industry with consumers in Germany, France, the UK, Spain, Italy, and others anticipated to register a steady demand throughout the forecast period, driving the overall market prospects. In addition, the proactive approach of businesses in identifying and leveraging new growth prospects positions the European Hemophilia B market for an upward trajectory, fostering both domestic and international interest. Leading brands operating in the industry are emphasizing effective marketing strategies, innovative product offerings, and a keen understanding of consumer preferences.
Asia Pacific Hemophilia B Market Size Outlook- an attractive hub for opportunities for both local and global companies
The increasing prevalence of indications, robust healthcare expenditure, and increasing investments in healthcare infrastructure drive the demand for Hemophilia B in Asia Pacific. In particular, China, India, and South East Asian Hemophilia B markets present a compelling outlook for 2030, acting as a magnet for both domestic and multinational manufacturers seeking growth opportunities. Similarly, with a burgeoning population and a rising middle class, India offers a vast consumer market. Japanese and Korean companies are quickly aligning their strategies to navigate changes, explore new markets, and enhance their competitive edge. Our report utilizes in-depth interviews with industry experts and comprehensive data analysis to provide a comprehensive outlook of 6 major markets in the region.
Latin America Hemophilia B Market Size Outlook- Continued urbanization and rising income levels
Rising income levels contribute to greater purchasing power among consumers, spurring consumption and creating opportunities for market expansion. Continued urbanization and rising income levels are expected to sustainably drive consumption growth in the medium to long term.
Middle East and Africa Hemophilia B Market Size Outlook- continues its upward trajectory across segments
Robust demand from Middle Eastern countries including Saudi Arabia, the UAE, Qatar, Kuwait, and other GCC countries supports the overall Middle East Hemophilia B market potential. Fueled by increasing healthcare expenditure of individuals, growing population, and high prevalence across a few markets drives the demand for Hemophilia B.
Hemophilia B Market Company Profiles
The global Hemophilia B market is characterized by intense competitive conditions with leading companies opting for aggressive marketing to gain market shares. The report presents business descriptions, SWOT analysis, growth strategies, and financial profiles. Leading companies included in the study are Aspen Holdings, Baxter International Inc, Bayer AG, Bristol Myers Squibb Company, Emcure Pharmaceuticals, EMERGENT, F. Hoffmann-La Roche Ltd, Fresenius Kabi AG, Gilead Sciences Inc, Grifols S.A., GlaxoSmithKline Plc, Hikma Pharmaceuticals PLC, Mylan N.V., Teva Pharmaceutical Industries Ltd.
Recent Hemophilia B Market Developments
The global Hemophilia B market study presents recent market news and developments including new product launches, mergers, acquisitions, expansions, product approvals, and other updates in the industry.
Hemophilia B Market Report Scope
Parameters: Revenue, Volume Price
Study Period: 2023 (Base Year); 2018- 2023 (Historic Period); 2024- 2030 (Forecast Period)
Currency: USD; (Upon request, can be provided in Euro, JPY, GBP, and other Local Currency)
Qualitative Analysis
By Type
Stationary 3D and 4D Ultrasound Devices
Portable 3D and 4D Ultrasound Devices
By Display
Color Ultrasound
B/W Ultrasound
By Portability
Trolley or Cart-Based Ultrasound Systems
Compact/Handheld Ultrasound Systems
Point-of-Pare (PoC) Ultrasound Systems
By Application
Radiology or General Imaging
Obstetrics or Gynecology
Cardiology
Urology
Vascular
Orthopedic and Musculoskeletal
Pain Management
Others
By End-User
Hospitals
Surgical Centers and Diagnostic Centers
Maternity Centers
Ambulatory Care Centers
Research and Academia
Others
Geographical Segmentation:
Aspen Holdings
Baxter International Inc
Bayer AG
Bristol Myers Squibb Company
Emcure Pharmaceuticals
EMERGENT
F. Hoffmann-La Roche Ltd
Fresenius Kabi AG
Gilead Sciences Inc
Grifols S.A.
GlaxoSmithKline Plc
Hikma Pharmaceuticals PLC
Mylan N.V.
Teva Pharmaceutical Industries Ltd
Formats Available: Excel, PDF, and PPT
The future of hemophilia B treatment is influenced by advancements in gene therapy, extended half-life factor IX products, and novel therapeutic modalities aimed at improving clotting factor replacement therapy for patients with hemophilia B. Key trends include the development of gene-based therapies utilizing adeno-associated viral vectors or mRNA technology to achieve sustained expression of functional factor IX, potentially offering a curative treatment option for this X-linked bleeding disorder. Additionally, the introduction of extended half-life factor IX products with improved pharmacokinetics and reduced dosing frequency enhances convenience and adherence to prophylactic treatment regimens, reducing the risk of spontaneous bleeds and long-term joint damage. Moreover, the exploration of non-factor replacement approaches, such as RNA interference (RNAi) and gene editing techniques, offers potential for alternative treatment modalities for patients with inhibitors or poor response to conventional factor IX replacement therapy..
Hemophilia B Market Drivers, Trends, Opportunities, and Growth Opportunities
This comprehensive study discusses the latest trends and the most pressing challenges for industry players and investors. The Hemophilia B market research analyses the global market trends, key drivers, challenges, and opportunities in the industry. In addition, the latest Future of Hemophilia B survey report provides the market size outlook across types, applications, and other segments across the world and regions. It provides data-driven insights and actionable recommendations for companies in the Hemophilia B industry.
Key market trends defining the global Hemophilia B demand in 2024 and Beyond
The industry continues to remain an attractive hub for opportunities for both domestic and global vendors. As the market evolves, factors such as emerging market dynamics, demand from end-user sectors, a growing patient base, changes in consumption patterns, and widening distribution channels continue to play a major role.
Hemophilia B Market Segmentation- Industry Share, Market Size, and Outlook to 2030
The Hemophilia B industry comprises a wide range of segments and sub-segments. The rising demand for these product types and applications is supporting companies to increase their investment levels across niche segments. Accordingly, leading companies plan to generate a large share of their future revenue growth from expansion into these niche segments. The report presents the market size outlook across segments to support Hemophilia B companies scaling up production in these sub-segments with a focus on expanding into emerging countries.
Key strategies adopted by companies within the Hemophilia B industry
Leading Hemophilia B companies are boosting investments to capitalize on untapped potential and future possibilities across niche market segments and surging demand conditions in key regions. Further, companies are leveraging advanced technologies to unlock opportunities and achieve operational excellence. The report provides key strategies opted for by the top 10 Hemophilia B companies.
Hemophilia B Market Study- Strategic Analysis Review
The Hemophilia B market research report dives deep into the qualitative factors shaping the market, empowering you to make informed decisions-
- Industry Dynamics: Porter's Five Forces analysis to understand bargaining power, competitive rivalry, and threats that impact long-term strategy formulation.
- Strategic Insights: Provides valuable perspectives on key players and their approaches based on comprehensive strategy analysis.
- Internal Strengths and Weaknesses: Develop targeted strategies to leverage strengths, address weaknesses, and capitalize on market opportunities.
- Future Possibilities: Prepare for diverse outcomes with in-depth scenario analysis. Explore potential market disruptions, technology advancements, and economic changes.
The Hemophilia B industry report provides a detailed analysis and outlook of revenue generated by companies from 2018 to 2023. Further, with actual data for 2023, the report forecasts the market size outlook from 2024 to 2030 in three case scenarios- low case, reference case, and high case scenarios.
Hemophilia B Country Analysis and Revenue Outlook to 2030
The report analyses 22 countries worldwide including the key driving forces and market size outlook from 2021 to 2030. In addition, region analysis across Asia Pacific, Europe, the Middle East, Africa, North America, and South America is included in the study. For each of the six regions, the market size outlook by segments is forecast for 2030.
North America Hemophilia B Market Size Outlook- Companies plan for focused investments in a changing environment
The US continues to remain the market leader in North America, driven by a large consumer base, the presence of well-established providers, and a strong end-user industry demand. Leading companies focus on new product launches in the changing environment. The US economy is expected to grow in 2024 (around 2.2% growth in 2024), potentially driving demand for various Hemophilia B market segments. Similarly, Strong end-user demand is encouraging Canadian Hemophilia B companies to invest in niche segments. Further, as Mexico continues to strengthen its trade relations and invest in technological advancements, the Mexico Hemophilia B market is expected to experience significant expansion, offering lucrative opportunities for both domestic and international stakeholders.
Europe Hemophilia B Market Size Outlook-Companies investing in assessing consumers, categories, competitors, and capabilities
The German industry remains the major market for companies in the European Hemophilia B industry with consumers in Germany, France, the UK, Spain, Italy, and others anticipated to register a steady demand throughout the forecast period, driving the overall market prospects. In addition, the proactive approach of businesses in identifying and leveraging new growth prospects positions the European Hemophilia B market for an upward trajectory, fostering both domestic and international interest. Leading brands operating in the industry are emphasizing effective marketing strategies, innovative product offerings, and a keen understanding of consumer preferences.
Asia Pacific Hemophilia B Market Size Outlook- an attractive hub for opportunities for both local and global companies
The increasing prevalence of indications, robust healthcare expenditure, and increasing investments in healthcare infrastructure drive the demand for Hemophilia B in Asia Pacific. In particular, China, India, and South East Asian Hemophilia B markets present a compelling outlook for 2030, acting as a magnet for both domestic and multinational manufacturers seeking growth opportunities. Similarly, with a burgeoning population and a rising middle class, India offers a vast consumer market. Japanese and Korean companies are quickly aligning their strategies to navigate changes, explore new markets, and enhance their competitive edge. Our report utilizes in-depth interviews with industry experts and comprehensive data analysis to provide a comprehensive outlook of 6 major markets in the region.
Latin America Hemophilia B Market Size Outlook- Continued urbanization and rising income levels
Rising income levels contribute to greater purchasing power among consumers, spurring consumption and creating opportunities for market expansion. Continued urbanization and rising income levels are expected to sustainably drive consumption growth in the medium to long term.
Middle East and Africa Hemophilia B Market Size Outlook- continues its upward trajectory across segments
Robust demand from Middle Eastern countries including Saudi Arabia, the UAE, Qatar, Kuwait, and other GCC countries supports the overall Middle East Hemophilia B market potential. Fueled by increasing healthcare expenditure of individuals, growing population, and high prevalence across a few markets drives the demand for Hemophilia B.
Hemophilia B Market Company Profiles
The global Hemophilia B market is characterized by intense competitive conditions with leading companies opting for aggressive marketing to gain market shares. The report presents business descriptions, SWOT analysis, growth strategies, and financial profiles. Leading companies included in the study are Aspen Holdings, Baxter International Inc, Bayer AG, Bristol Myers Squibb Company, Emcure Pharmaceuticals, EMERGENT, F. Hoffmann-La Roche Ltd, Fresenius Kabi AG, Gilead Sciences Inc, Grifols S.A., GlaxoSmithKline Plc, Hikma Pharmaceuticals PLC, Mylan N.V., Teva Pharmaceutical Industries Ltd.
Recent Hemophilia B Market Developments
The global Hemophilia B market study presents recent market news and developments including new product launches, mergers, acquisitions, expansions, product approvals, and other updates in the industry.
Hemophilia B Market Report Scope
Parameters: Revenue, Volume Price
Study Period: 2023 (Base Year); 2018- 2023 (Historic Period); 2024- 2030 (Forecast Period)
Currency: USD; (Upon request, can be provided in Euro, JPY, GBP, and other Local Currency)
Qualitative Analysis
- Pricing Analysis
- Value Chain Analysis
- SWOT Profile
- Market Dynamics- Trends, Drivers, Challenges
- Porter’s Five Forces Analysis
- Macroeconomic Impact Analysis
- Case Scenarios- Low, Base, High
By Type
Stationary 3D and 4D Ultrasound Devices
Portable 3D and 4D Ultrasound Devices
By Display
Color Ultrasound
B/W Ultrasound
By Portability
Trolley or Cart-Based Ultrasound Systems
Compact/Handheld Ultrasound Systems
Point-of-Pare (PoC) Ultrasound Systems
By Application
Radiology or General Imaging
Obstetrics or Gynecology
Cardiology
Urology
Vascular
Orthopedic and Musculoskeletal
Pain Management
Others
By End-User
Hospitals
Surgical Centers and Diagnostic Centers
Maternity Centers
Ambulatory Care Centers
Research and Academia
Others
Geographical Segmentation:
- North America (3 markets)
- Europe (6 markets)
- Asia Pacific (6 markets)
- Latin America (3 markets)
- Middle East Africa (5 markets)
Aspen Holdings
Baxter International Inc
Bayer AG
Bristol Myers Squibb Company
Emcure Pharmaceuticals
EMERGENT
F. Hoffmann-La Roche Ltd
Fresenius Kabi AG
Gilead Sciences Inc
Grifols S.A.
GlaxoSmithKline Plc
Hikma Pharmaceuticals PLC
Mylan N.V.
Teva Pharmaceutical Industries Ltd
Formats Available: Excel, PDF, and PPT
1. EXECUTIVE SUMMARY
1.1 Hemophilia B Market Overview and Key Findings, 2024
1.2 Hemophilia B Market Size and Growth Outlook, 2021- 2030
1.3 Hemophilia B Market Growth Opportunities to 2030
1.4 Key Hemophilia B Market Trends and Challenges
1.4.1 Hemophilia B Market Drivers and Trends
1.4.2 Hemophilia B Market Challenges
1.5 Competitive Landscape and Key Players
1.6 Competitive Analysis- Growth Strategies Adopted by Leading Hemophilia B Companies
2. HEMOPHILIA B MARKET SIZE OUTLOOK TO 2030
2.1 Hemophilia B Market Size Outlook, USD Million, 2021- 2030
2.2 Hemophilia B Incremental Market Growth Outlook, %, 2021- 2030
2.3 Segment Snapshot, 2024
3. HEMOPHILIA B MARKET- STRATEGIC ANALYSIS REVIEW
3.1 Porter's Five Forces Analysis
* Threat of New Entrants
* Threat of Substitutes
* Intensity of Competitive Rivalry
* Bargaining Power of Buyers
* Bargaining Power of Suppliers
3.2 Value Chain Analysis
3.3 SWOT Analysis
4. HEMOPHILIA B MARKET SEGMENTATION ANALYSIS AND OUTLOOK
4.1 Market Segmentation and Scope
4.2 Market Breakdown by Type, Application, and Other Segments, 2021-2030
By Type
Stationary 3D and 4D Ultrasound Devices
Portable 3D and 4D Ultrasound Devices
By Display
Color Ultrasound
B/W Ultrasound
By Portability
Trolley or Cart-Based Ultrasound Systems
Compact/Handheld Ultrasound Systems
Point-of-Pare (PoC) Ultrasound Systems
By Application
Radiology or General Imaging
Obstetrics or Gynecology
Cardiology
Urology
Vascular
Orthopedic and Musculoskeletal
Pain Management
Others
By End-User
Hospitals
Surgical Centers and Diagnostic Centers
Maternity Centers
Ambulatory Care Centers
Research and Academia
Others
4.3 Growth Prospects and Niche Opportunities, 2023- 2030
4.4 Regional comparison of Market Growth, CAGR, 2023-2030
5. REGION-WISE MARKET OUTLOOK TO 2030
5.1 Key Findings for Asia Pacific Hemophilia B Market, 2025
5.2 Asia Pacific Hemophilia B Market Size Outlook by Type, 2021- 2030
5.3 Asia Pacific Hemophilia B Market Size Outlook by Application, 2021- 2030
5.4 Key Findings for Europe Hemophilia B Market, 2025
5.5 Europe Hemophilia B Market Size Outlook by Type, 2021- 2030
5.6 Europe Hemophilia B Market Size Outlook by Application, 2021- 2030
5.7 Key Findings for North America Hemophilia B Market, 2025
5.8 North America Hemophilia B Market Size Outlook by Type, 2021- 2030
5.9 North America Hemophilia B Market Size Outlook by Application, 2021- 2030
5.10 Key Findings for South America Hemophilia B Market, 2025
5.11 South America Pacific Hemophilia B Market Size Outlook by Type, 2021- 2030
5.12 South America Hemophilia B Market Size Outlook by Application, 2021- 2030
5.13 Key Findings for Middle East and Africa Hemophilia B Market, 2025
5.14 Middle East Africa Hemophilia B Market Size Outlook by Type, 2021- 2030
5.15 Middle East Africa Hemophilia B Market Size Outlook by Application, 2021- 2030
6. COUNTRY-WISE MARKET SIZE OUTLOOK TO 2030
6.1 US Hemophilia B Market Size Outlook and Revenue Growth Forecasts
6.2 US Hemophilia B Industry Drivers and Opportunities
6.3 Canada Market Size Outlook and Revenue Growth Forecasts
6.4 Canada Hemophilia B Industry Drivers and Opportunities
6.6 Mexico Market Size Outlook and Revenue Growth Forecasts
6.6 Mexico Hemophilia B Industry Drivers and Opportunities
6.7 Germany Market Size Outlook and Revenue Growth Forecasts
6.8 Germany Hemophilia B Industry Drivers and Opportunities
6.9 France Market Size Outlook and Revenue Growth Forecasts
6.10 France Hemophilia B Industry Drivers and Opportunities
6.11 UK Market Size Outlook and Revenue Growth Forecasts
6.12 UK Hemophilia B Industry Drivers and Opportunities
6.13 Spain Market Size Outlook and Revenue Growth Forecasts
6.14 Spain Hemophilia B Industry Drivers and Opportunities
6.16 Italy Market Size Outlook and Revenue Growth Forecasts
6.16 Italy Hemophilia B Industry Drivers and Opportunities
6.17 Rest of Europe Market Size Outlook and Revenue Growth Forecasts
6.18 Rest of Europe Hemophilia B Industry Drivers and Opportunities
6.19 China Market Size Outlook and Revenue Growth Forecasts
6.20 China Hemophilia B Industry Drivers and Opportunities
6.21 India Market Size Outlook and Revenue Growth Forecasts
6.22 India Hemophilia B Industry Drivers and Opportunities
6.23 Japan Market Size Outlook and Revenue Growth Forecasts
6.24 Japan Hemophilia B Industry Drivers and Opportunities
6.26 South Korea Market Size Outlook and Revenue Growth Forecasts
6.26 South Korea Hemophilia B Industry Drivers and Opportunities
6.27 Australia Market Size Outlook and Revenue Growth Forecasts
6.28 Australia Hemophilia B Industry Drivers and Opportunities
6.29 South East Asia Market Size Outlook and Revenue Growth Forecasts
6.30 South East Asia Hemophilia B Industry Drivers and Opportunities
6.31 Rest of Asia Pacific Market Size Outlook and Revenue Growth Forecasts
6.32 Rest of Asia Pacific Hemophilia B Industry Drivers and Opportunities
6.33 Brazil Market Size Outlook and Revenue Growth Forecasts
6.34 Brazil Hemophilia B Industry Drivers and Opportunities
6.36 Argentina Market Size Outlook and Revenue Growth Forecasts
6.36 Argentina Hemophilia B Industry Drivers and Opportunities
6.37 Rest of South America Market Size Outlook and Revenue Growth Forecasts
6.38 Rest of South America Hemophilia B Industry Drivers and Opportunities
6.39 Middle East Market Size Outlook and Revenue Growth Forecasts
6.40 Middle East Hemophilia B Industry Drivers and Opportunities
6.41 Africa Market Size Outlook and Revenue Growth Forecasts
6.42 Africa Hemophilia B Industry Drivers and Opportunities
7. HEMOPHILIA B MARKET OUTLOOK ACROSS SCENARIOS
7.1 Low Growth Case
7.2 Reference Growth Case
7.3 High Growth Case
8. HEMOPHILIA B COMPANY PROFILES
8.1 Profiles of Leading Hemophilia B Companies in the Market
8.2 Business Descriptions, SWOT Analysis, and Growth Strategies
8.3 Financial Performance and Key Metrics
Aspen Holdings
Baxter International Inc
Bayer AG
Bristol Myers Squibb Company
Emcure Pharmaceuticals
EMERGENT
F. Hoffmann-La Roche Ltd
Fresenius Kabi AG
Gilead Sciences Inc
Grifols S.A.
GlaxoSmithKline Plc
Hikma Pharmaceuticals PLC
Mylan N.V.
Teva Pharmaceutical Industries Ltd
9. APPENDIX
9.1 Scope of the Report
9.2 Research Methodology and Data Sources
9.3 Glossary of Terms
9.4 Market Definitions
9.5 Contact Information
1.1 Hemophilia B Market Overview and Key Findings, 2024
1.2 Hemophilia B Market Size and Growth Outlook, 2021- 2030
1.3 Hemophilia B Market Growth Opportunities to 2030
1.4 Key Hemophilia B Market Trends and Challenges
1.4.1 Hemophilia B Market Drivers and Trends
1.4.2 Hemophilia B Market Challenges
1.5 Competitive Landscape and Key Players
1.6 Competitive Analysis- Growth Strategies Adopted by Leading Hemophilia B Companies
2. HEMOPHILIA B MARKET SIZE OUTLOOK TO 2030
2.1 Hemophilia B Market Size Outlook, USD Million, 2021- 2030
2.2 Hemophilia B Incremental Market Growth Outlook, %, 2021- 2030
2.3 Segment Snapshot, 2024
3. HEMOPHILIA B MARKET- STRATEGIC ANALYSIS REVIEW
3.1 Porter's Five Forces Analysis
* Threat of New Entrants
* Threat of Substitutes
* Intensity of Competitive Rivalry
* Bargaining Power of Buyers
* Bargaining Power of Suppliers
3.2 Value Chain Analysis
3.3 SWOT Analysis
4. HEMOPHILIA B MARKET SEGMENTATION ANALYSIS AND OUTLOOK
4.1 Market Segmentation and Scope
4.2 Market Breakdown by Type, Application, and Other Segments, 2021-2030
By Type
Stationary 3D and 4D Ultrasound Devices
Portable 3D and 4D Ultrasound Devices
By Display
Color Ultrasound
B/W Ultrasound
By Portability
Trolley or Cart-Based Ultrasound Systems
Compact/Handheld Ultrasound Systems
Point-of-Pare (PoC) Ultrasound Systems
By Application
Radiology or General Imaging
Obstetrics or Gynecology
Cardiology
Urology
Vascular
Orthopedic and Musculoskeletal
Pain Management
Others
By End-User
Hospitals
Surgical Centers and Diagnostic Centers
Maternity Centers
Ambulatory Care Centers
Research and Academia
Others
4.3 Growth Prospects and Niche Opportunities, 2023- 2030
4.4 Regional comparison of Market Growth, CAGR, 2023-2030
5. REGION-WISE MARKET OUTLOOK TO 2030
5.1 Key Findings for Asia Pacific Hemophilia B Market, 2025
5.2 Asia Pacific Hemophilia B Market Size Outlook by Type, 2021- 2030
5.3 Asia Pacific Hemophilia B Market Size Outlook by Application, 2021- 2030
5.4 Key Findings for Europe Hemophilia B Market, 2025
5.5 Europe Hemophilia B Market Size Outlook by Type, 2021- 2030
5.6 Europe Hemophilia B Market Size Outlook by Application, 2021- 2030
5.7 Key Findings for North America Hemophilia B Market, 2025
5.8 North America Hemophilia B Market Size Outlook by Type, 2021- 2030
5.9 North America Hemophilia B Market Size Outlook by Application, 2021- 2030
5.10 Key Findings for South America Hemophilia B Market, 2025
5.11 South America Pacific Hemophilia B Market Size Outlook by Type, 2021- 2030
5.12 South America Hemophilia B Market Size Outlook by Application, 2021- 2030
5.13 Key Findings for Middle East and Africa Hemophilia B Market, 2025
5.14 Middle East Africa Hemophilia B Market Size Outlook by Type, 2021- 2030
5.15 Middle East Africa Hemophilia B Market Size Outlook by Application, 2021- 2030
6. COUNTRY-WISE MARKET SIZE OUTLOOK TO 2030
6.1 US Hemophilia B Market Size Outlook and Revenue Growth Forecasts
6.2 US Hemophilia B Industry Drivers and Opportunities
6.3 Canada Market Size Outlook and Revenue Growth Forecasts
6.4 Canada Hemophilia B Industry Drivers and Opportunities
6.6 Mexico Market Size Outlook and Revenue Growth Forecasts
6.6 Mexico Hemophilia B Industry Drivers and Opportunities
6.7 Germany Market Size Outlook and Revenue Growth Forecasts
6.8 Germany Hemophilia B Industry Drivers and Opportunities
6.9 France Market Size Outlook and Revenue Growth Forecasts
6.10 France Hemophilia B Industry Drivers and Opportunities
6.11 UK Market Size Outlook and Revenue Growth Forecasts
6.12 UK Hemophilia B Industry Drivers and Opportunities
6.13 Spain Market Size Outlook and Revenue Growth Forecasts
6.14 Spain Hemophilia B Industry Drivers and Opportunities
6.16 Italy Market Size Outlook and Revenue Growth Forecasts
6.16 Italy Hemophilia B Industry Drivers and Opportunities
6.17 Rest of Europe Market Size Outlook and Revenue Growth Forecasts
6.18 Rest of Europe Hemophilia B Industry Drivers and Opportunities
6.19 China Market Size Outlook and Revenue Growth Forecasts
6.20 China Hemophilia B Industry Drivers and Opportunities
6.21 India Market Size Outlook and Revenue Growth Forecasts
6.22 India Hemophilia B Industry Drivers and Opportunities
6.23 Japan Market Size Outlook and Revenue Growth Forecasts
6.24 Japan Hemophilia B Industry Drivers and Opportunities
6.26 South Korea Market Size Outlook and Revenue Growth Forecasts
6.26 South Korea Hemophilia B Industry Drivers and Opportunities
6.27 Australia Market Size Outlook and Revenue Growth Forecasts
6.28 Australia Hemophilia B Industry Drivers and Opportunities
6.29 South East Asia Market Size Outlook and Revenue Growth Forecasts
6.30 South East Asia Hemophilia B Industry Drivers and Opportunities
6.31 Rest of Asia Pacific Market Size Outlook and Revenue Growth Forecasts
6.32 Rest of Asia Pacific Hemophilia B Industry Drivers and Opportunities
6.33 Brazil Market Size Outlook and Revenue Growth Forecasts
6.34 Brazil Hemophilia B Industry Drivers and Opportunities
6.36 Argentina Market Size Outlook and Revenue Growth Forecasts
6.36 Argentina Hemophilia B Industry Drivers and Opportunities
6.37 Rest of South America Market Size Outlook and Revenue Growth Forecasts
6.38 Rest of South America Hemophilia B Industry Drivers and Opportunities
6.39 Middle East Market Size Outlook and Revenue Growth Forecasts
6.40 Middle East Hemophilia B Industry Drivers and Opportunities
6.41 Africa Market Size Outlook and Revenue Growth Forecasts
6.42 Africa Hemophilia B Industry Drivers and Opportunities
7. HEMOPHILIA B MARKET OUTLOOK ACROSS SCENARIOS
7.1 Low Growth Case
7.2 Reference Growth Case
7.3 High Growth Case
8. HEMOPHILIA B COMPANY PROFILES
8.1 Profiles of Leading Hemophilia B Companies in the Market
8.2 Business Descriptions, SWOT Analysis, and Growth Strategies
8.3 Financial Performance and Key Metrics
Aspen Holdings
Baxter International Inc
Bayer AG
Bristol Myers Squibb Company
Emcure Pharmaceuticals
EMERGENT
F. Hoffmann-La Roche Ltd
Fresenius Kabi AG
Gilead Sciences Inc
Grifols S.A.
GlaxoSmithKline Plc
Hikma Pharmaceuticals PLC
Mylan N.V.
Teva Pharmaceutical Industries Ltd
9. APPENDIX
9.1 Scope of the Report
9.2 Research Methodology and Data Sources
9.3 Glossary of Terms
9.4 Market Definitions
9.5 Contact Information
